Iran has been here before. For decades the country has gone through cycles of protest and repression at the hands of the Islamic Republic. What makes this cycle different? In this episode of ...

The Rip follows a group of detectives who come across millions of dollars in cash during an investigation. The reveal of the money throws into question who can be trusted and who is out for themselves ...

Note: This story contains spoilers from “His & Hers” Episode 6. For series star and executive producer, Tessa Thompson, the toughest part of crafting the “His & Hers” twisty ending was ensuring it ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Netflix’s latest Korean blockbuster The Great Flood has surged to the top of the platform’s global charts for nonglobal films, but audiences are divided over its cryptic ending and philosophical twist ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Staking is one of the most common ways crypto holders earn rewards simply by holding and committing their tokens to a blockchain network. Often described as “earning passive income in crypto,” staking ...

AI on the JVM accelerates: New frameworks like Embabel, Koog, Spring AI, and LangChain4j drive rapid adoption of AI-native and AI-assisted development in Java. Java 25 anchors a modern baseline: The ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...